# A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

> **NCT02212106** · PHASE4 · COMPLETED · sponsor: **Seqirus** · enrollment: 402 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)
- **BIOLOGICAL:** Comparator Quadrivalent Influenza Virus Vaccine

## Key facts

- **NCT ID:** NCT02212106
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2015-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212106, "A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02212106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*